Recent 8-K filings for KAPA
Highest-materiality recent filing
Kairos Pharma reports ENV-105 plus apalutamide median PFS of 17.7 months vs 2 months in Phase 2 mCRPC trial (P=0.0008)
- Interim Phase 2 analysis showed a statistically significant PFS difference for ENV-105 plus apalutamide vs apalutamide alone (median 17.7 vs 2 months; P=0.0008).
- Kairos modified the Phase 2 protocol to enroll patients earlier, after PSA increase on an androgen signaling inhibitor, randomized to enzalutamide alone or with ENV-105.
-
Interim Phase 2 analysis showed a statistically significant PFS difference for ENV-105 plus apalutamide vs apalutamide alone (median 17.7 vs 2 months; P=0.0008).
-
Kairos Pharma collaborates with Bayer to test ENV-105 + XOFIGO in mCRPC; market up to $1.3B
Bayer to supply radium for Kairos' study of ENV-105 (carotuximab) with XOFIGO in metastatic castration-resistant prostate cancer.
-
Kairos Pharma reports zero Grade 3+ toxicities from ENV-105 in Phase 1 NSCLC trial
Zero Grade 3+ toxicities from ENV-105 in 13 patients with advanced EGFR-mutated NSCLC.
-
Kairos Pharma acquires exclusive worldwide rights to CL-273 from Celyn Therapeutics
Acquired 100% worldwide rights to CL-273, a pan-EGFR inhibitor for EGFR-mutant NSCLC, from Celyn Therapeutics (backed by OrbiMed and Torrey Pines).
-
Kairos Pharma to Present Phase 2 Prostate Cancer Data at ESMO 2025
On October 7, 2025, Kairos issued press release announcing ESMO Congress presentation in Berlin from October 17-21.
-
Kairos Pharma reports positive Phase 2 interim efficacy for ENV105 in mCRPC; median PFS >13 months
Median PFS >13 months in 8 evaluable patients with mCRPC who failed prior hormone therapy.
-
Kairos Pharma to host KOL event Sept 18 for ENV105 Phase 2 interim efficacy data
Virtual KOL event on Sept 18, 2025, at 5 p.m. ET to discuss interim efficacy results from ENV105 Phase 2 trial in advanced prostate cancer.
-
Kairos Pharma reports positive safety results from Phase 2 ENV-105 trial in mCRPC
No dose-limiting toxicities or unexpected adverse events in first 10 patients.
-
Kairos Pharma presents KROS101 preclinical data at ASCO; shows superiority over TRX518
KROS101 is a small molecule GITR ligand agonist with dual mechanisms: promotes T effector proliferation and reduces T reg suppression.
-
Kairos Pharma closes $3.5M PIPE offering of pre-funded units and warrants
Sold 2,500,000 Pre-Funded Units at $1.399/unit, raising gross proceeds of $3,497,500.
-
Kairos Pharma raises $3.5M in PIPE offering at $1.40/unit with warrants
Raises $3.5M gross from sale of units at $1.40/Common Unit and $1.399/Pre-Funded Unit.
-
Kairos Pharma enters $900K biomarker agreement with PreCheck for ENV105 trials
Agreement with PreCheck Health Services for biomarker screening in ongoing lung (NCT05401110) and prostate (NCT05534646) cancer trials.
-
Kairos Pharma closes $6.2M IPO; shares trade on NYSE American under KAPA
Closed IPO of 1,550,000 shares at $4.00/share; gross proceeds $6,200,000.
Materiality & sentiment trend
Max materiality 0.80 · Median 0.55 · Most common event other_material